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Abstract
Here we investigate the effects of the novel transforming growth factor-β receptor I (TGF-βRI) serine/threonine
kinase inhibitor LY2109761 on glioblastoma when combined with the present clinical standard combination reg-
imen radiotherapy and temozolomide (TMZ). Human GBM U87 (methylated MGMT promoter), T98 (unmethylated
MGMT promoter), and endothelial cells (HUVECs) were treated with combinations of LY2109761, TMZ, and ra-
diation. We found that LY2109761 reduced clonogenic survival of U87 and T98 cells and further enhanced the
radiation-induced anticlonogenicity. In addition, LY2109761 had antimigratory and antiangiogenic effects in Matrigel
migration and tube formation assays. In vivo, in human xenograft tumors growing subcutaneously on BALB/c nu/nu
mice, LY2109761 delayed tumor growth alone and in combination with fractionated radiation and TMZ. Interestingly,
as expected, the methylated U87 model was more sensitive to TMZ than the unmethylated T98 model in all experi-
ments, whereas the opposite was found for LY2109761. Moreover, with respect to tumor angiogenesis, while
LY2109761 decreased the glioblastoma proliferation index (Ki-67) and the microvessel density (CD31 count), the rel-
ative pericyte coverage (α-SMA/CD31 ratio) increased in particular after triple therapy, suggesting a vascular normal-
ization effect induced by LY2109761. This normalization could be attributed in part to a decrease in the Ang-2/Ang-1
messenger RNA ratio. LY2109761 also reduced tumor blood perfusion as quantified by noninvasive dynamic
contrast-enhanced magnetic resonance imaging. Together, the data indicate that the addition of a TGF-βRI kinase
inhibitor to the present clinical standard (radiation plus TMZ) has the potential to improve clinical outcome in human
glioblastoma, especially in patients with unmethylated MGMT promoter status.
Neoplasia (2011) 13, 537–549
Abbreviations: DCE-MRI, dynamic contrast-enhanced magnetic resonance imaging; DEF, dose enhancement factor; GBM, glioblastoma multiforme; HUVEC, human um-
bilical vein endothelial cell; MGMT, O6-methylguanine methyltransferase; MVD, microvessel density; RT, radiation therapy; TGF-βRI, transforming growth factor β receptor I;
TMZ, temozolomide
Address all correspondence to: Peter E. Huber, MD, PhD, Department of Radiation Oncology, German Cancer Research Center (DKFZ)/University of Heidelberg Medical
Center, 280 Im Neuenheimer Feld, Heidelberg 69120, Germany. E-mail: p.huber@dkfz.de
1This work was supported in part by grants from Deutsche Krebshilfe 106997, DFG National Priority Research Program the Tumor-Vessel Interface (SPP1190), Kompetenzverbund
Strahlenforschung (KVSF, 03NUK004A, C) of Bundesministerien fuer Bildung, Forschung und Umwelt (BMBF/BMU), and the Tumorzentrum Heidelberg-Mannheim/
NCT Heidelberg.
M.L. is an employee of Lilly, Inc, Indianapolis, IN. P.E.H. received a research grant from Lilly, Inc., Indianapolis, IN.
2This article refers to supplementary materials, which are designated by Tables W1 and W2 and are available online at www.neoplasia.com.
3These authors share first authorship.
Received 2 February 2011; Revised 6 April 2011; Accepted 7 April 2011
Copyright © 2011 Neoplasia Press, Inc. All rights reserved 1522-8002/11/$25.00
DOI 10.1593/neo.11258
www.neoplasia.com
Volume 13 Number 6 June 2011 pp. 537–549 537
Introduction
Glioblastoma multiforme (GBM) is the most common and the most
malignant primary brain tumor in adults with a high degree of mor-
bidity and mortality [1]. Despite intensive conventional treatment
protocols, the prognosis of this tumor is still dismal [2]. One strategy
to improve treatment outcome is to add more specific signaling in-
hibitors to the nonsurgical standard treatment regimen of chemora-
diotherapy with temozolomide (TMZ). A promising target candidate
is the inhibition of transforming growth factor-β (TGF-β) signaling.
TGF-β is a multifunctional ubiquitous polypeptide cytokine that
binds and activates a membrane receptor serine/threonine kinase
complex. On TGF-β binding, the receptor complex phosphorylates
the transcription factors Smad2 and Smad3, which then bind to
Smad4 and accumulate in the nucleus, where they regulate transcrip-
tion of target genes [3]. The tumor suppressor function of TGF-β
signaling is well established [4,5]. However, in some tumor types,
and specifically in high-grade glioma, TGF-β becomes an oncogenic
factor [6,7] and acts as a highly potent suppressor of immune re-
actions [8], an inductor of angiogenesis [9], and a promoter of cell
motility and malignant invasion. The overexpression of TGF-β li-
gands has been reported in various malignant entities, such as malig-
nant glioma [10,11], pancreatic carcinoma [12,13], and colorectal
carcinoma [14,15]. In human malignant glioma, elevated levels of
TGF-β are associated with high tumor grade, advanced tumor stages,
and poor disease prognosis [10,16]. By virtue of the pivotal role of
TGF-β in malignant glioma, a novel approach has been developed
for the treatment of high-grade glioma based on the specific inhibi-
tion of TGF-β signaling pathway. Several small-molecule inhibitors
of the TGF-β receptor kinase have been developed as promising thera-
peutic tools for the treatment of malignant glioma [17]. LY2109761,
a novel TGF-βRI inhibitor, has shown a SMAD2-selective inhibi-
tory profile with antitumor activity in various tumor models, such
as breast cancer [18], colorectal cancer [19], pancreatic cancer [20],
and hepatocellular carcinoma [21]. However, to our best knowledge,
no study has been reported about the effects of LY2109761 on glio-
blastoma in combination with other therapies.
Considering that chemoradiotherapy with TMZ is the standard
treatment approach in GBM after primary diagnosis, the addition
of a TGF-β inhibitor seems a promising approach in this setting.
For the present studies, we hypothesized that combining external beam
radiotherapy with a TGF-β inhibitor augments tumor cell radiosen-
sitivity because tumors have been shown to release TGF-β after radi-
ation resulting in increased resistance to radiation [22,23]. Another
potential anticipated beneficial effect of a TGF-β inhibitor is the re-
duction of glioma cell migration because sublethal doses of photon
irradiation have been shown to promote migration and invasiveness
of glioma cells [24,25]. We hypothesized that TGF-β inhibition could
counteract this undesirable biologic effect of radiotherapy. Finally, we
also expected potential antiangiogenic effects of blocking TGF-β sig-
naling because tumor-derived TGF-β has been shown to cooperate
with angiogenesis-promoting factors [26], such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (bFGF).
Here, we investigated in vitro and in vivo effects of the small-
molecule TGF-βRI inhibitor LY2109761 in combination with radio-
therapy ± TMZ. In addition to tumor response, we were primarily
interested in parameters that characterize the microenvironment and
tumor physiology. To this end, we applied noninvasive radiologic im-
aging and evaluated blood perfusion and tumor angiogenesis using
quantitative magnetic resonance imaging (MRI). Overall, the study
shows that the combination of LY2109761 with radiotherapy and
TMZ seems to have promising antitumor activity and provides a ra-
tionale to evaluate this or similar strategies in clinical trials.
Materials and Methods
Cell Cultures and Treatment Conditions
Primary isolated human umbilical vein endothelial cells (HUVECs;
Promocell, Heidelberg, Germany) were cultured up to passage 8. Cells
were maintained in culture at 37°C with 5% CO2 and 95% humidity
in serum-reduced (5% fetal calf serum) modified Promocell medium
supplemented with 2 ng/ml VEGF, 4 ng/ml bFGF. Human glioblas-
toma (U87MG) tumor cells (TumorbankDKFZHeidelberg, Germany)
and fast-growing T98 [27] were cultured in Dulbecoo modified Eagle
medium with 10% fetal calf serum. LY2109761 was kindly provided by
Eli Lilly (Indianapolis, IN), constituted in dimethyl sulfoxide (10 mM),
and stored at −20°C. TMZ (Essex Pharma, Munich, Germany) was
constituted in dimethyl sulfoxide (100 mM) and stored at −20°C. Cell
exposures with the drugs were performed 2 hours before irradiating
with 6-MV x-rays (Mevatron; Siemens, Erlangen, Germany) at a dose
rate of 2.5 Gy/min.
Clonogenic Assay
For clonogenic assays increasing numbers of cells (102 to 5 × 104)
were plated in 25-cm2 flasks (Becton Dickinson, Heidelberg, Germany),
and exposed to compound(s) and irradiation followed by incubation at
37°C for 10 to 14 days. Colonies formed were stained with crystal violet
(Sigma, Germany), those with at least 50 cells were counted by micro-
scopic inspection, and plating efficiency as well as clonogenic survival
was calculated. The linear quadratic equation was fitted to data sets to
generate survival curves. Dose enhancement factor (DEF) for drugs
was calculated at the 10% survival level (DEF0.1, control radiation
dose divided by the treated radiation dose). DEF values greater than
1.0 indicate enhancement of radiosensitivity.
Proliferation Assay
A total of 1 × 105 HUVECs were seeded on 25-cm2 collagen-coated
flasks overnight at standard conditions followed by exposure with dif-
ferent treatments and thereafter incubated for another 72 hours, and
the total number of living cells was counted after trypan blue staining.
Matrigel Invasion/Migration Assay
The invasion/migration of glioblastoma and endothelial cells in vitro
was measured on Matrigel-coated (0.78 mg/ml) transwell inserts
with 8-μm pore size (Becton Dickinson). Cells were trypsinized and
500 μl of cell suspension (1 × 105 cells/ml) per experiment were
added to transwells in triplicate. Chemoattractant medium contain-
ing VEGF and bFGF (750 μl) was added to the lower wells. After
12 hours of incubation, cells that had invaded the underside of the
membrane were fixed and stained with Diff-Quik II solution (Dade
Behring AG, Germany) and sealed on slides. Migrating cells were
counted under microscopy.
Tube Formation Assay
To evaluate in vitro angiogenesis activity, tube formation assays
were performed with HUVEC. Twenty-four-well plates were coated
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with 300 μl of Matrigel (Becton Dickinson). HUVECs (5 × 104 cells)
were suspended in 500 μl of medium containing various concentra-
tions of compound(s) and/or receiving 4 Gy of irradiation and then
added on the polymerized Matrigel. After incubating at 37°C for
6 hours, cells were fixed and stained with Diff-Quik II reagents (Dade
Behring AG, Germany), photographed, and counted.
Gene Expression Analysis by Quantitative Real-time
Polymerase Chain Reaction
At 6 hours after treatment, U87MG cells were solubilized and ho-
mogenized in TRIzol (Invitrogen, Carlsbad, CA). Total RNA was iso-
lated according to the manufacturer’s instruction, and purity and
integrity of the RNA were assessed with Agilent 2100 BioAnalyzer
(Agilent Technologies, Palo Alto, CA). Then quantitative real-time
polymerase chain reaction (PCR) was performed using QuantiTect
Primer assay (Qiagen, Hilden, Germany) and QuantiTect SYBRGreen
RT-PCR Kit (no. 204243; Qiagen) on a LightCycler 480 instrument
(Roche Diagnostics, Mannheim, Germany). The detection and quan-
tification involved the following steps: reverse transcription at 50°C
for 30 minutes, initial activation at 95°C for 15 minutes, followed
by 40 cycles of denaturation at 94°C for 15 seconds, annealing at
55°C for 30 seconds, and extension at 72°C for 30 seconds. Fluores-
cence data collection was performed at the extension step at 72°C.
The relative expression of the target genes was calculated by normal-
izing the Cp (crossing point) values with those of housekeeping gene
GAPDH. All assays were performed in triplicates.
Xenograft Tumor Study in Mice
Animal studies were performed according to the rules for care and
use of experimental animals and approved by the local and gov-
ernmental Animal Care Committee instituted be the German Gov-
ernment (Regierungspraesidium, Karlsruhe). Human glioblastoma
xenografts were established by injecting 5 × 106 U87MG or T98 cells
subcutaneously (s.c.) into the right hind limb of 6- to 8 week-old
BALB/c athymic nude mice (Charles River Laboratories, Sulzfeld,
Germany). Tumor growth was followed until tumor volume reached
approximately 150 mm3 as measured with calipers and calculated by
the formula: volume (V ) = length (a) × width (b) × width (b) × 0.5.
Then animals were randomized into eight groups (13-15 mice per
group with three mice scheduled for histology after day 14 of treat-
ment for the U87MG model and 8 to 10 mice per group for the
T98 model): control, LY2109761 only, TMZ only, irradiation only,
LY2109761 combined with TMZ, LY2109761 combined with radia-
tion, TMZ combined with radiation, and LY2109761 combined with
TMZ and radiation. Starting on day 0, TMZ was administered intra-
peritoneally (i.p.) in PBS at 50 mg/kg five times weekly. LY2109761
was dissolved in the NaCMC/SLS/PVP/antifoam oral vehicle (1% so-
dium carboxymethylcellulose, 0.5% sodium lauryl sulfate, 0.085% PVP,
and 0.05% antifoam; Eli Lilly) and administered orally at 50 mg/kg
twice daily (days 1-5 of each week) until the end of observation. Tumors
were irradiated with a fractionated schedule (5 × 2 Gy) starting on day 0
for five consecutive days using a 6-MV LINAC (Siemens).
Immunohistochemistry
For histologic analysis, U87MG xenografts were harvested from
three additional animals per treatment group, 10 days after the start
of therapy. Cryostat tumor sections were stained with mouse anti-
CD31 IgG2a antibody (1:100; BD Pharmingen, San Jose, CA) for
30 minutes at 37°C followed by staining with Alexa Fluor 555–labeled
goat antimouse IgG2 antibody (1:400; Invitrogen) for 30 minutes
at 37°C. Then the sections were incubated with rabbit anti–α-SMA
antibody (1:100; Abcam, Cambridge, UK) for 30 minutes at 37°C and
followed by incubation with Alexa Fluor 488–labeled antirabbit IgG2
antibody (1:400; Invitrogen) for 30 minutes at 37°C. Then mounting
medium containing 4′,6 diamidino-2-phenylindole (Vector Labora-
tories, Burlingame, CA) was applied to stain all nuclei. Similarly, the
Ki-67/4′,6 diamidino-2-phenylindole staining was performed. Primary
antibody and dilution were as follows: Rabbit anti–Ki-67 (Abcam) at a
concentration of 5mg/ml digital fluorescent images were obtained using
a Nikon Eclipse E600 microscope (Duesseldorf, Germany) equipped
with a Nikon digital sight DS-U1 camera.
Dynamic Contrast-Enhanced Magnetic Resonance Imaging
MRI was performed on a clinical 1.5-T whole-body MRI system
(Siemens Magnetom Vision) using a custom-made small-animal sole-
noid Tx/Rx radiofrequency coil. Dynamic contrast-enhanced (DCE)
MRI was performed using a two-dimensional T1-weighted saturation
recovery gradient echo sequence (saturation recovery turbo fast low
angle shot, TR = 13 milliseconds, TE = 5.3 milliseconds, T REC =
300 milliseconds, flip angle = 12°, matrix = 128 × 48, resolution =
0.5 × 0.5 × 2.0 mm3, average = 4) [28]. A total number of 120 dy-
namic images were acquired with a temporal resolution of 7.5 sec-
onds, resulting in a total scan time of 15 minutes. The contrast agent
Gadomer (Bayer Schering Pharma, Berlin, Germany; molecular weight =
17 kDa; 0.05 mmol/kg diluted in 0.9% NaCl to a total volume of
100 μl) was injected manually through the tail vein (infusion time =
5 seconds). The DCE-MRI postprocessing was done based on the
two-compartment model developed by Brix et al. [29] using Dynalab
software (MeVis Research, Bremen, Germany). Functional parameters
amplitude A (describes relative change in signal intensity after the con-
trast agent injection relative to precontrast values) as a measure for rela-
tive blood volume in the tumors and kep (describes the volume transfer
constant between the extravascular extracellular space and the blood
plasma) as a measure for fluid exchange between vasculature and extra-
vascular space were calculated pixelwise, color-coded, and overlaid on
the morphologic MR images.
Statistical Analysis
The unpaired two-tailed t test was used for the comparison of param-
eters between groups. The Kaplan-Meier method was used to deter-
mine the mean time to tumor progression (TTP), and a log-rank test
was used to compare the differences between each treatment condition.
A value of P < .05 was considered significant. The statistical analysis
was performed using the software package Statistika 6.0 (Statsoft,
Hamburg, Germany).
Results
Clonogenic Survival
Treatment of glioblastoma cells with increasing concentrations of
LY2109761 and TMZ showed a dose-response relationship distinct
for each cell line and each compound (Figure 1A). U87MG cells
displayed greater sensitivity to TMZ exposure than T98 (Figure 1A,
left panel ). Conversely, T98 cells were markedly more sensitive to
LY2109761 than U87MG cells (Figure 1A, right panel ). Accordingly,
the concentration of LY2109761 inducing a surviving fraction of
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∼80% was approximately 10 μM for U87MG and 5 μM for T98,
respectively. For subsequent combination clonogenic assay experi-
ments, doses of LY2109761 and TMZ for moderate toxicity were used:
U87MG = 10 μM LY2109761 and 5 μM TMZ; T98 = 5 μM
LY2109761 and a TMZ concentration of 50 μM, which corresponds
to the serum concentration achieved in humans using the standard
protocol of 150 mg/m2 per day [30].
Next we investigated whether LY2109761 and TMZ would act
as radiosensitizers in glioblastoma cells. The surviving fraction was
normalized for the cytotoxicity induced by the compound(s) and
Figure 1. Clonogenic survival of glioblastoma cell lines after each treatment. (A) The effects of LY2109761 and TMZ exposures on the
clonogenic survival of U87MG (left) and T98 (right). (B) The effects of LY2109761 and TMZ on the radiosensitivity of U87MG (left) and
T98 (right). Bars indicate SD; Ly, LY2109761; points, mean; TMZ, temozolomide. (C) Detailed analysis of clonogenic survival for RT ± Ly ±
TMZ in U87MG and T98 depicted as bars. All effects in this figure are normalized to the control experiment. Bars indicate ±SD; columns,
mean; Ly, LY2109761 (10 μM for U87MG; 5 μM for T98); RT, radiation (4 Gy); TMZ, temozolomide (5 μM for U87MG; 50 μM for T98). *P<
.05 versus controls. **P< .05 versus RT. @P< .05 versus RT, Ly + RT, and TMZ + RT. #Nonsignificant versus RT. *#P< .05 versus TMZ +
RT and nonsignificant versus Ly + RT.
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the linear quadratic equation was fitted to data sets (Figure 1B). Both
LY2109761 and TMZ showed radiosensitizing effects on U87MG
cells with a DEF0.1 of 1.29 and 1.22, respectively. The combina-
tion of LY2109761 and TMZ further increased the radiosensitivity
of U87MG cells with a DEF0.1 of 1.51 (Figure 1B, left panel, and
C and Table W1). Whereas the addition of LY2109761 led to an in-
crease of radiosensitivity in T98 cells (DEF0.1 = 1.24), no radiosen-
sitizing effect was observed by TMZ and no further increase of
radiosensitivity was achieved after the addition of TMZ to the combi-
nation treatment with LY2109761 and radiation in T98 cells (Fig-
ure 1B, right panel, and C and Table W1).
Endothelial Cell Proliferation
To investigate the effects of different treatment regimens on endo-
thelial cell proliferation as the effector cells of angiogenesis, a cell
count proliferation assay was performed in HUVEC. We found that
each treatment (LY2109761 at 5 μM, TMZ at 50 μM, and radiation
at 4 Gy) decreased the proliferation of HUVEC in a range of 40% to
60% (P < .05). Dual or triple combination treatment further reduced
the cell number (Figure 3A, P < .05). Triple combination showed a
superior inhibitory effect on endothelial cell proliferation compared
with radiation and TMZ (P < .05).
Cell Invasion/Migration
To investigate the effects of different treatment regimens on glio-
blastoma and endothelial cell invasion/migration, Transwell invasion/
migration assays were performed. We found that radiation (4 Gy)
and/or TMZ (50 μM) treatment enhanced U87MG and HUVEC
migration through the extracellular matrix (Matrigel) compared with
control (P < .05). Importantly, LY2109761 (10 μM) strongly sup-
pressed the constitutive and treatment-induced migration in U87MG
and HUVEC (P < .05). There was no significant difference in the mi-
gratory cell number between each LY2109761 including regimen (Fig-
ures 2, A and B, and 3, B and C ). In addition, transwell invasion/
migration assays in T98 cells displayed similar results (data not shown).
Tube Formation
The sprouting of endothelial cells and formation of tubes are cru-
cial steps in the angiogenic process. Control HUVEC spread and
aligned with each other and formed a rich meshwork of branching
anastomosing capillary-like tubules with multicentric junctions. This
Figure 2. The effects of each treatment on tumor cell migration/invasion. U87MG cell migration/invasion was determined by counting
cells that had migrated to the lower side of an invasion chamber 12 hours after treatment. (A) Stained cells in representative fields
(100×). (B) The number of cells that had migrated shown as histogram: bars indicate SD; columns, mean; Ly, LY2109761 (10 μM);
RT, radiation (4 Gy); TMZ, temozolomide (50 μM). *P < .05 versus control. **P < .05 versus control and treatment without LY2109761.
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Figure 3. The effects of each treatment on endothelial cell proliferation, migration, and tube formation. (A) HUVEC proliferation was
determined by cell count 72 hours after exposure to the following treatments: LY2109761 (Ly, 10 μM), TMZ (50 μM), radiation (RT,
4 Gy), the dual or triple combination. Relative number of cells is shown as a histogram: bars indicate SD; columns, mean. *P < .05
versus control. **P < .05 versus control and respective single treatment. ***P < .05 versus all other treatments. (B) HUVEC migration
was determined by counting cells that had migrated to the lower side of an invasion chamber 12 hours after treatment. Stained cells
in representative fields (100×). (C) The number of HUVEC that had migrated is shown as a histogram: bars indicate SD; columns, mean.
*P < .05 versus control. **P < .05 versus control and treatment without LY2109761. (D) The ability of HUVEC to form tubule-like struc-
tures when plated on Matrigel was determined for cells in each treatment condition. Photographs of representative tube formation fields
are shown (100×).
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process was hardly influenced by either radiation and/or TMZ.
LY2109761 alone and in combination with radiation and/or TMZ
reduced and disorganized the tube-like structures (Figure 3D).
Gene Expression Changes of Ang-1 and Ang-2
As shown for U87MG quantitative real-time polymerase chain re-
action analysis revealed that the messenger RNA (mRNA) level of
Ang-1 remained unchanged for all treatment conditions (Figure 4).
However, LY2109761 (10 μmol) alone or in combination with TMZ
(50 μmol) and/or radiation (4 Gy) significantly reduced Ang-2 mRNA
expression, whereas a slight but not statistically significant increase of
Ang-2 expression was documented after treatment with TMZ and ra-
diation alone or their combination.
Glioblastoma Tumor Growth in Mice In Vivo
Next we determined whether the enhancement of antitumor ef-
fects of LY2109761 and TMZ in vitro could be translated into an
in vivo tumor model. Tumor growth delay assays were performed
in s.c. U87MG and T98 glioblastoma xenograft mouse models
and the TTP, as defined by tumors reaching three times their baseline
size [31], was calculated using the tumor volumes from the individ-
ual mice in each group. For U87MG tumors, as shown in Figure 5A
and Table W2, animals of the control group showed a progressive
increase of tumor volume with a mean TTP of only 11.1 ± 1.79 days.
All monotherapies resulted in significant tumor growth delay and sub-
sequent prolonged TTP (radiation therapy (RT) = 29.7 ± 7.17 days,
LY2109761 = 32.0 ± 6.28 days, TMZ = 64.3 ± 9.14 days). Radia-
tion treatment plus LY2109761 or TMZ (RT + LY2109761 = 62.1 ±
8.29 days, RT + TMZ = 75.4 ± 8.29 days) was significantly more
effective than the respective monotherapies (P < .05). The combina-
tion of LY2109761 and TMZ (79.9 ± 7.15 days) had a tendency to
enhance tumor growth delay versus TMZ monotherapy, but this
combinatorial effect was not marked and the difference was not sta-
tistically significant (P > .05). Importantly, the triple combination
of all three therapies was significantly more effective than all other
regimens showing the largest effect on tumor growth delay (95.9 ±
2.39 days). For T98 tumors, as shown in Figure 5B and Table W2,
LY2109761 or radiation monotherapy induced marked tumor
growth delay, with an increased mean TTP (RT = 20.9 ± 4.32 days,
LY2109761 = 16.5 ± 2.53 days) compared with controls (10.2 ±
1.26 days). Their combination resulted in a further increased TTP
(30.78 ± 6.16 days) in a supra-additive manner. However, no statisti-
cally significant increase of TTP was observed by TMZ monotherapy
(11.9 ± 1.58 days) and no further increase of TTP was achieved after
the addition of TMZ to LY2109761 or radiation or their combination.
Immunohistochemistry
The Ki-67 index in U87MG tumors as a global proliferation marker
was reduced in all treated groups (Figure 6). Tumors after dual treat-
ments had lower Ki-67 indices than after single therapies. Triple com-
bination resulted in a further decrease of the Ki-67 index compared
with all dual combinations (P < .05; Figure 6B). Antiangiogenic ther-
apeutic effects in tumors can be associated with reduced microvessel
density (MVD), and an increased ratio of α-SMA/CD31–positive tu-
mor blood vessels after therapy indicates a tumor vascular normaliza-
tion process. As shown in Figure 6C and D, a significant decrease in
microvessel count (CD31) and an increase in the fraction of pericyte
Figure 3. (continued).
Figure 4. mRNA expression of Ang-1 and Ang-2 of U87MG cells in
the different treatment conditions versus untreated controls. Bars
indicate SD; columns, mean; Ly, LY2109761; RT, radiation; TMZ,
temozolomide. *P < .05 versus control.
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coverage (α-SMA/CD31) were observed after single treatment with
LY2109761, TMZ, or irradiation (P < .05). Dual combinations with
LY2109761 further reduced vessel count and increased pericyte cover-
age compared with single treatments (P < .05). The triple combination
Figure 5. In vivo growth of U87MG and T98 tumor xenografts.
BALB/c nu/nu mice with U87MG (A) and T98 (B) human glioblas-
toma growing s.c. were treated as described in Materials and
Methods. Points: mean of tumor volume normalized to the day
of therapy start (d0). Bars indicate SE. *P < .05 versus control.
**P < .05 versus control and each monotherapy. ***P < .05 ver-
sus control, each monotherapy and dual therapy. &P > .05 versus
TMZ monotherapy, #P > .05 versus control. ##P > .05 versus con-
trol and each monotherapy. ###P > .05 versus control, each mono-
therapy and dual therapy.
Figure 6. Immunohistochemical evaluation of each treatment on
the proliferation and intratumoral vasculature within U87MG xeno-
grafts. Tumor-bearing mice were killed on days 14 after the start of
treatment (three animals per group). Tumors were excised and
processed as described in Materials and Methods. (A) Represen-
tative examples for the detection of Ki-67 in tumor sections from
various treatment groups (200×). (B) Quantitative comparison of
the Ki-67 index in the tumor sections from the eight groups of ani-
mals. (C) Representative examples for the double staining of CD31/
α-SMA (red, CD31; green, α-SMA) in tumor sections from various
treatment groups. Original magnification, ×200. (D) Quantitative
comparison of tumor vessel (left panel) and fraction of pericyte cov-
erage (right panel) in the tumor sections from the eight groups of
animals. *P < .05 versus control. **P < .05 versus control and re-
spective single treatment. ***P < .05 versus all other treatments.
*#P < .05 versus Ly + RT and TMZ + RT but nonsignificant versus
Ly + TMZ. Bars indicate SD; columns, mean.
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Figure 6. (continued).
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showed the lowest vessel number and highest fraction of pericyte cov-
erage compared with all other groups (P < .05).
In Vivo Imaging of Tumor Blood Perfusion Using DCE-MRI
To investigate the tumor perfusion, three U87MG tumor-bearing
mice randomized to histologic examination from each group were
subjected to DCE-MRI on day 14 directly before killing. Amplitudes
and kep were measured in regions of interest covering the total tu-
mor (Figure 7). A significant decrease in the amplitude level as a mea-
sure for tumor blood volume was observed under all monotherapies
(LY2109761, TMZ, and RT) compared with the control group (P <
.05). Combination treatments, both dual and triple, did not fur-
ther decrease the amplitude value. Surprisingly, the exchange rate
constant kep, which is a compound parameter highly influenced by
vessel permeability, increased significantly after LY2109761 treat-
ment (P < .05), whereas radiation and TMZ tended to decrease the
exchange rate kep.
Discussion
The clinical prognosis for glioblastoma patients is still extremely
poor. Almost all patients die with or without surgery and additional
radiotherapy within 2 years from the diagnosis. The recent addition
of the classic chemotherapeutic agent TMZ in various schedules con-
current to radiotherapy with later maintenance has only prolonged
the median survival for a few months [2]. This situation rationalizes
the search for an integration of suitable novel and effective drugs
into the treatment. The inhibition of the TGF-β signaling pathway
is considered a promising strategy in treating glioblastoma. One
reason is that the overexpression of TGF-β is associated with prolif-
eration, invasion/migration, and angiogenesis in glioma [10,11,16].
  
 
 
Figure 7. MRI with amplitude and kep parameters of U87MG tumors under different treatments. Three tumor-bearing mice from each
group were subjected to DCE-MRI measurement on day 14 before histologic examination. Amplitudes and kep were measured in re-
gions of interest covering the total tumor. (A) Representative examples of color-coded amplitude and kep parameter maps from different
treatment groups. (B) Quantitative comparison of the amplitude (left panel) and kep (right panel) parameter of the tumor from the eight
groups of animals. Bars indicate SD; columns, mean; Ly, LY2109761; RT, radiation; TMZ, temozolomide. *P < .05 versus control. #Non-
significant (P > .05) versus control.
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In the present study, we investigated a trimodal glioblastoma treatment
regimen combining LY2109761, a novel TGF-βRI kinase inhibitor,
with radiotherapy and the chemotherapeutic agent TMZ. We show
that the addition of LY2109761 to fractionated radiation ± TMZ
markedly increased the antitumor effect of the standard treatment in
human glioblastoma in vitro and in vivo. The here suggested regimen
can, in principle, be transferred into the clinic because the combina-
tion of radiotherapy with TMZ is the nonsurgical standard of care for
most glioblastoma patients.
The beneficial combination effect is presumably based on multiple
effects of LY2109761 on both tumor cells and the tumor micro-
environment. Our in vitro data show that LY2109761 has both di-
rect cytotoxic effects and radiosensitizing effects on glioblastoma cells
(U87MG and T98). TMZ demonstrated significant cytotoxic and
radiosensitizing effects on U87MG cells, even at low concentrations,
whereas little such effects of TMZ were observed in T98 cells even at
higher, clinically relevant concentrations. This differential response
between these two glioblastoma cells to TMZ was also observed in
our animal experiment, which can be explained by their difference in
O6-methylguanine methyltransferase (MGMT) methylation and ex-
pression status. It has been reported that the promoter of MGMT in
U87MG glioblastoma is methylated and expression is low, whereas
in T98 cells, the promoter of MGMT is unmethylated and thus the
protein expression is positive [32,33]. The protective effect of MGMT
activity against the cytotoxic effects of alkylating agents has been
demonstrated in several human glioma cell lines [33,34] as well as
in the clinical setting. Hegi et al. [35] reported that glioblastoma
patients with unmethylated MGMT promoters did not seem to expe-
rience a survival benefit from the addition of TMZ to radiation. Im-
portantly, in the present study, no protective effect of MGMT activity
was observed against the antitumor effect of LY2109761. Conversely,
the unmethylated T98 cells were found to be approximately 1.5-fold
more sensitive to LY2109761 than the methylated U87MG at the
10% survival fraction end point. Furthermore, our in vivo data showed
that the addition of LY2109761 markedly increased antitumor activity
of radiotherapy ± TMZ, resulting in increased tumor growth delay in
both MGMT-positive and -negative tumors. These data suggest that
the combination of LY2109761 with chemoradiotherapy might be a
promising multimodality treatment approach in glioblastoma, includ-
ing for those patients whose tumors express MGMTand may therefore
benefit less from TMZ.
Local invasive growth is a key feature of glioblastoma, and the high
invasion/migration character is considered to be a major therapeutic
obstacle for glioblastoma treatment. A number of signaling pathways
can be constitutively activated in migrating glioma cells, rendering
these cells resistant to cytotoxic insults [36,37]. Moreover, ionizing
radiation has been reported to be able to promote tumor invasion/
migration itself [24,38]. This context provides another rationale for
the use of LY2109761 in glioblastoma treatment because we found
that LY2109761 was able to reduce glioblastoma and HUVEC cell
migration/invasion. More importantly, the addition of LY2109761 to
radiotherapy ± TMZ also markedly reduced the treatment-induced
invasion/migration of glioblastoma cells. These findings are in agree-
ment with reports demonstrating the implication of TGF-β in glioma
cell invasion and migration [39] and with findings showing that the
inhibition of TGF-β signaling suppressed cell invasion/migration in
glioma and other types of cancers [18–21,40]. Together, our data in-
dicate that LY2109761 is a potent antimigratory compound for glio-
blastoma. The data also rationalize the addition of LY2109761 or a
substance with similar properties to conventional radiotherapy and/
or chemotherapy to counteract the potential undesired promigratory
effect of radiotherapy.
The LY2109761 effects on tumor physiology, blood perfusion, and
tumor angiogenesis provide another reason for the beneficial antitumor
combination effects with radiation and TMZ in vivo. Antiangiogenic
therapy has shown promise in the treatment of various types of cancers
alone and in combination with conventional chemotherapy and/or ra-
diotherapy [41,42]. In human glioma cells, TGF-β has been shown to
be a potent inducer of VEGF and αvβ3 integrin expression [43,44],
indicating that TGF-β signaling has a role in tumor angiogenesis
[9,26]. Accordingly, we found that LY2109761 strongly inhibited pro-
liferation and migration of endothelial cells and, consequently, disabled
new vessel formation, as shown in tube formation assays. Further,
LY2109761 demonstrated strong antiangiogenic effects in vivo as
shown by reducing MVD in glioblastoma in mice. Interestingly,
LY2109761 also enhanced the fraction of pericyte coverage (α-SMA/
CD31 ratio) of tumor vessels alone and in combination with radio-
therapy ± chemotherapy. The interpretation of this process as a vas-
cular normalization effect suggests improved physiological conditions
for both radiotherapy and chemotherapy, which both depend on func-
tional blood perfusion and/or ample oxygen supply [45]. Because glio-
blastoma in patients are also highly vascularized and express TGF-β,
targeting TGF-β might thus also exhibit antiangiogenic effects in the
clinical setting.
These histologic findings are in excellent agreement with quanti-
tative blood perfusion measurements using DCE-MRI. Applying the
two-compartment model of Brix et al. [29], DCE-MRI showed a
significant decrease of the parameter amplitude in all treated groups
including the monotherapies, which corresponds to the decrease of
MVD under all three monotherapies. This decrease in amplitude can
be attributed mainly to the reduction of relative blood volume in the
tumors [46]. However, combination therapies (both dual and triple)
did not further decrease the DCE-MRI amplitude value, reflecting a
vascular normalization process leading to improved tumor perfusion
in agreement with the increased pericyte coverage of the vasculature.
For the exchange parameter kep, which is mainly influenced by vessel
permeability, a decrease of kep could have been expected especially
after LY2109761 treatment in analogy to prototypical antiangiogenic
agents such as bevacizumab. These antibodies for vascular endothelial
growth factor also reduce vascular permeability. However, our results
show an increase of kep after LY2109761 and a basically unchanged
kep after radiation and/or TMZ. Similar effects on kep after antiangio-
genic therapy have been reported in a recent DCE-MRI tumor study
[28]. The puzzling finding that antiangiogenics increase kep may have
two possible explanations. First, vessel normalization under anti-
angiogenic treatment could result in a more laminar flow and thus
higher perfusion, which leads to an increase in kep. Second, therapy-
induced apoptosis or other forms of endothelial cell death may in-
crease vessel fenestration and permeability and, consequently, also
kep. Conversely, our finding on DCE-MRI after therapy may have
implications for the interpretation of DCE-MRI functional imaging
parameters, in particular, in the context of antiangiogenic therapy
and tumor vessel normalization.
The angiopoietin ligands (Ang-1 and Ang-2) and their receptor
(Tie2) have crucial roles in the tumor angiogenic switch, inflamma-
tion, metastasis, and lymphangiogenesis [47]. Increased expression of
Ang-2 and higher Ang-2/Ang-1 ratios in tumors correlate with poor
prognosis in many cancers. Recent reports have shown that they may
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also be involved in vascular normalization of glioblastoma [48].
Tumor vessel normalization effect of LY2109761 suggested by im-
munohistochemical and DCE-MRI data prompted us to analyze
the gene expression of Ang-1 and Ang-2 in tumor cells and study
whether their mRNA was modulated by LY2109761 treatment. As
expected, LY2109761, alone or in combination with TMZ and/or ra-
diation, was associated with a significant reduction of Ang-2 mRNA,
but Ang-1 remained unchanged, thus leading to a decrease in Ang-2/
Ang-1 ratios, which may partly account for the vascular normaliza-
tion effect of LY2109761 observed in our experiment condition.
In summary, the presented preclinical study supports the concept
of adding a TGF-βRI inhibitor to radiotherapy ± TMZ regimen in
the treatment of glioblastoma. The data suggested that the addition of
LY2109761 increased the antitumor effects of radiotherapy ± chemo-
therapy both in vivo and in vitro. The beneficial therapeutic effects
of LY2109761 are presumably a combination of direct cytotoxic,
antimigratory/anti-invasive, and antiangiogenic properties, along with
radiosensitizing effects.
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Table W1. Radiation Doses That Reduce Cell Clonogenic Survival to 10% (D0.1) Calculated by
Fitting the Linear Quadratic Equation to Clonogenic Survival after Treatment with Radiation
Alone and in Combination with LY2109761 and/or TMZ.
Cell Treatment D0.1 (Gy) DEF
U87MG RT alone 7.03
RT + Ly 5.44 1.29
RT + TMZ 5.76 1.22
RT + Ly + TMZ 4.67 1.51
T98 RT alone 6.15
RT + Ly 4.97 1.24
RT + TMZ 6.09 1.01
RT + Ly + TMZ 4.90 1.26
Dose enhancement factor (DEF) was defined as the quotient of D0.1 RT/D0.1 RT + drug(s). DEF
greater than 1 indicates greater than independent toxicity in combined treatment.
Ly indicates LY2109761.
Table W2. Effects of Each Treatment on TTP of U87MG and T98 Tumor Xenografts.
Tumor Model Group TTP (Mean ± SD; Days) TTP Control (Days)
U87MG Control 11.1 ± 1.79
Ly 32.0 ± 6.28 20.9
TMZ 64.3 ± 9.14 53.2
RT 29.7 ± 7.17 18.6
Ly + TMZ 79.9 ± 7.15 68.8
Ly + RT 62.1 ± 8.29 53.8
TMZ + RT 75.4 ± 8.29 64.3
Ly + TMZ + RT 95.9 ± 2.39 84.8
T98 Control 10.1 ± 1.26
Ly 16.5 ± 2.53 6.4
TMZ 11.9 ± 1.58 1.8
RT 20.9 ± 4.32 10.8
Ly + TMZ 18.1 ± 4.41 8.0
Ly + RT 30.8 ± 6.16 20.7
TMZ + RT 22.6 ± 5.07 12.5
Ly + TMZ + RT 34.3 ± 7.13 24.2
TTP is defined as the time when tumor volume increased three times from the baseline value for each
mouse. TTP control is defined as TTP difference between each treatment group and control group.
Ly indicates LY2109761.
